NCT06892483 Breastmilk in Response to a Bout of Exercise
| NCT ID | NCT06892483 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Infant Development |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-04-21 |
| Primary Completion | 2027-10-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-04-21 with a primary completion date of 2027-10-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to unveil the mechanistic benefits of a bout of postpartum maternal exercise on infant health that are provided by breastmilk.
Eligibility Criteria
Exclusion Criteria: * Active coronary artery disease or heart failure. * Participation in a structured exercise program ≥ 1 day/week in the "inactive" subcohort or \< 3 days per week in the "active" subcohort. * A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples: * Abnormal liver function test results (Transaminase \>2 times the upper limit of normal * Abnormal renal function test results (calculated GFR \<60 mL/min/1.73m2); * If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study * Uncontrolled thyroid disease (TSH undetectable or \>10 mlU/L); testing required within three months prior to admission for subjects with a goiter, positive antibodies, or who are on thyroid hormone replacement, and within one year otherwise * Abuse of alcohol or recreational drugs * Active tobacco smoking within the past 3 months * Infectious process not anticipated to resolve prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis). * Uncontrolled arterial hypertension (Resting diastolic blood pressure \>90 mmHg and/or systolic blood pressure \>160 mmHg) at the time of screening. * A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol * Active pregnancy * Restrictions on Use of Other Drugs or Treatments: * Any other medication believed to be a contraindication to the subject's participation.
Contact & Investigator
Mark Pataky, Ph.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06892483 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Infant Development. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06892483 currently recruiting?
Yes, NCT06892483 is actively recruiting participants. Contact the research team at Szymanski.Linda@mayo.edu for enrollment information.
Where is the NCT06892483 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06892483 clinical trial?
NCT06892483 is sponsored by Mayo Clinic. The principal investigator is Mark Pataky, Ph.D. at Mayo Clinic. The trial plans to enroll 60 participants.